Variable Involvement of the Perivascular Retinal Tissue in Carbonic Anhydrase Inhibitor–Induced Relaxation of Porcine Retinal Arterioles In Vitro

2007 ◽  
Vol 48 (10) ◽  
pp. 4688 ◽  
Author(s):  
Anne Katrine Kehler ◽  
Kim Holmgaard ◽  
Anders Hessellund ◽  
Christian Aalkjaer ◽  
Toke Bek
Keyword(s):  
Carbonic Anhydrase ◽  
Carbonic Anhydrase Inhibitor ◽  
Retinal Tissue ◽  
Retinal Arterioles

Polypharmacology of epacadostat: a potent and selective inhibitor of the tumor associated carbonic anhydrases IX and XII

2019 ◽  
Vol 55 (40) ◽  
pp. 5720-5723 ◽  
Author(s):  
Andrea Angeli ◽  
Marta Ferraroni ◽  
Alessio Nocentini ◽  
Silvia Selleri ◽  
Paola Gratteri ◽  
...  
Keyword(s):  
Carbonic Anhydrase ◽  
Selective Inhibitor ◽  
Carbonic Anhydrase Inhibitor ◽  
Carbonic Anhydrases ◽  
Indoleamine 2,3 Dioxygenase

Epacadostat (EPA), a selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, has been investigatedin vitroas a human (h) Carbonic Anhydrase Inhibitor (CAI).

CHLOROTHIAZIDE

PEDIATRICS ◽  
1958 ◽  
Vol 22 (2) ◽  
pp. 236-237
Author(s):  
JOHN D. CRAWFORD
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Carbonic Anhydrase ◽  
Renal Insufficiency ◽  
Chronic Renal Insufficiency ◽  
Free Water ◽  
Carbonic Anhydrase Inhibitor ◽  
Diuretic Agent

CHLOROTHIAZIDE is a new, orally effective diuretic agent chemically related to acetazolamide. Curiously, it is a considerably less potent carbonic anhydrase inhibitor, at least in vitro and, in vivo, its effect has been found additive to that of acetazolamide as it is to the action of the mercurials. Laragh's observations suggest that chlorothiazide inhibits the process of solute reabsorption which normally gives rise to "free" water in the urine. Thus, it may well have a locus of action in the kidney different from that of its chemical cousin or the mercury derivities. There have been optimistic reports of its efficacy in a variety of edema states including nephrosis, cirrhosis of the liver, congestive heart failure, acute hemorrhagic nephritis and chronic renal insufficiency.

scholarly journals Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro

2000 ◽  
Vol 97 (5) ◽  
pp. 2220-2224 ◽  
Author(s):  
S. Parkkila ◽  
H. Rajaniemi ◽  
A.-K. Parkkila ◽  
J. Kivela ◽  
A. Waheed ◽  
...  
Keyword(s):  
Carbonic Anhydrase ◽  
Cancer Cells ◽  
Renal Cancer ◽  
Carbonic Anhydrase Inhibitor

Sickle-cell Disease—New Method of Treatment

PEDIATRICS ◽  
1958 ◽  
Vol 21 (1) ◽  
pp. 21-21
Keyword(s):  
Sickle Cell Disease ◽  
Carbonic Anhydrase ◽  
Sickle Cell ◽  
Preliminary Report ◽  
Carbonic Anhydrase Inhibitor ◽  
Cell Disease ◽  
Molecular Rearrangement ◽  
Clinical Observations

This is a preliminary report of a new approach to treatment of sickle-cell disease based on the knowledge that the sickling phenomenon resides in a defect in the hemoglobin which, when deoxygenated, undergoes molecular rearrangement with consequent alteration of the shape of the erythrocyte. The sickle-cell phenomenon is not seen in fully oxygenated blood. It seemed reasonable to the authors to employ carbonic anhydrase inhibitor to control reduction of hemoglobin in sickle-cell disease to such an extent as to prevent the occurrence of sickling. The carbonic anhydrase inhibitor employed was acetazolamide (Diamox®). Experiments were conducted in vitro and also in vivo in a single Negro baby 8 months of age. Before treatment the patient's blood contained 18.7% sickled cells. One hour after 2 mg of acetazolamide per kilogram the percentage of sickled cells was reduced to 11.8%; 1 hour after 7 mg of acetazolamide per kilogram the percentage of sickled cells was reduced to 7.5%. At the time of this preliminary report the patient had been treated with acetazolamide for 29 days with an increase in the hemoglobin from 7.1 to 9.4 gm/100 ml. In a preliminary period of observation of 41 days before treatment the hemoglobin had declined during two separate episodes of hemolysis. The theory of the suggested mode of treatment is discussed. A detailed account of the clinical observations is to be the subject of a further report.

The Effect of a Carbonic Anhydrase Inhibitor, Diamox, On Human Pancreatic Secretion

1955 ◽  
Vol 29 (2) ◽  
pp. 262-279 ◽  
Author(s):  
David A. Dreiling ◽  
Henry D. Janowitz ◽  
Mark Halpern
Keyword(s):  
Carbonic Anhydrase ◽  
Pancreatic Secretion ◽  
Carbonic Anhydrase Inhibitor

Are Carbonic Anhydrases Suitable Targets to Fight Protozoan Parasitic Diseases?

2019 ◽  
Vol 25 (39) ◽  
pp. 5266-5278 ◽  
Author(s):  
Katia D'Ambrosio ◽  
Claudiu T. Supuran ◽  
Giuseppina De Simone
Keyword(s):  
Drug Resistance ◽  
Animal Models ◽  
Carbonic Anhydrase ◽  
Drug Target ◽  
Treatment Options ◽  
Parasitic Diseases ◽  
Carbonic Anhydrases ◽  
Extensive Drug Resistance ◽  
Protozoan Infections

Protozoans belonging to Plasmodium, Leishmania and Trypanosoma genera provoke widespread parasitic diseases with few treatment options and many of the clinically used drugs experiencing an extensive drug resistance phenomenon. In the last several years, the metalloenzyme Carbonic Anhydrase (CA, EC 4.2.1.1) was cloned and characterized in the genome of these protozoa, with the aim to search for a new drug target for fighting malaria, leishmaniasis and Chagas disease. P. falciparum encodes for a CA (PfCA) belonging to a novel genetic family, the η-CA class, L. donovani chagasi for a β-CA (LdcCA), whereas T. cruzi genome contains an α-CA (TcCA). These three enzymes were characterized in detail and a number of in vitro potent and selective inhibitors belonging to the sulfonamide, thiol, dithiocarbamate and hydroxamate classes were discovered. Some of these inhibitors were also effective in cell cultures and animal models of protozoan infections, making them of considerable interest for the development of new antiprotozoan drugs with a novel mechanism of action.

Sign in / Sign up

Export Citation Format

Share Document